Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. ALNY Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Alnylam Pharmaceuticals (ALNY)

Market Price (9/17/2025): $460.2 | Market Cap: $59.7 Bil
Sector: Health Care | Industry: Biotechnology

Alnylam Pharmaceuticals (ALNY)

Market Price (9/17/2025): $460.2
Market Cap: $59.7 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Low stock price volatility
Vol 12M is 44%		 Trading close to highs
Dist 52W High is -4.3%, Dist 3Y High is -4.3%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.9%
1   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.9%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.2%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.9%
0 Low stock price volatility
Vol 12M is 44%
1 Trading close to highs
Dist 52W High is -4.3%, Dist 3Y High is -4.3%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.9%
3 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.9%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.2%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.9%

Market Valuation

 9/17/252024202320222021
Share Price CYE$460.20$235.31$191.41$237.65$169.58
Market Cap CYE ($ Bil)59.730.424.029.320.3
Total Debt ($ Bil)1.31.31.31.31.0
Total Cash ($ Bil)2.62.72.42.22.4
Enterprise Value ($ Bil)58.331.725.330.621.3
Valuation Ratios     
P/S TTM25.413.413.127.923.8
P/EBIT TTM-284.0-127.5-76.6-29.8-28.3
P/E TTM-221.3-108.0-54.3-25.6-23.6
Sector Ratios     
P/S TTM (Sector)3.73.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/17/2520242023
Share Price CYE$460.20$235.31$191.41
Market Cap CYE ($ Bil)59.730.424.0
Total Debt ($ Bil)1.31.31.3
Total Cash ($ Bil)2.62.72.4
Enterprise Value ($ Bil)58.331.725.3
Valuation Ratios   
P/S TTM25.413.413.1
P/EBIT TTM-284.0-127.5-76.6
P/E TTM-221.3-108.0-54.3
Sector Ratios   
P/S TTM (Sector)3.73.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
ALNY Return13%30%40%-19%23%96%305%
Peers Return64%12%8%2%-11%5%90%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: IONS, SRPT, NTLA, ABBV, AMGN. See ALNY Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Better Bets than Alnylam Pharmaceuticals (ALNY)

 ALNYBetter Performance than ALNY
MetricValueIndustry (Biotechnology)
Rev Chg LTM17.2%INSM (21.2%), UTHR (17.6%), INCY (18.9%), NBIX (21.7%), BMRN (18.4%)
Rev Chg 3Y Avg40.8%BBIO (1225.0%), RYTM (137.5%), CYTK (824.6%), AXSM (699.5%), CRSP (380.7%)
Op Mgn LTM-4.9%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-1.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-3.2%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-0.5%ABBV (3.9%), AMGN (7.9%), GILD (7.4%), VRTX (3.6%), REGN (7.7%)
 ALNYBetter Performance than ALNY
MetricValueAll Other Sectors
Rev Chg LTM17.2%NVDA (71.6%), META (19.4%), AVGO (28.0%), PLTR (38.8%), AMD (27.2%)
Rev Chg 3Y Avg40.8%NVDA (92.0%), RCL (65.4%), APO (129.8%), NU (70.1%), RDDT (42.6%)
Op Mgn LTM-4.9%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-1.9%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-3.2%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-0.5%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.8%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Alnylam Pharmaceuticals Earnings Notes  
2Now Is Not The Time To Buy Alnylam Pharmaceuticals StockBuy or Fear 
3Day 5 of Gains Streak for Alnylam Pharmaceuticals Stock with 29% Return (vs. 78% YTD) [8/4/2025]Notification 
4ALNY Dip Buy Analysis  
5Alnylam Pharmaceuticals Market PriceMarket Price 
6Alnylam Pharmaceuticals Total Shareholder Return (TSR): 22.9% in 2024 and 11.5% 3-yr compounded annual returns (above peer average)  
7Alnylam Pharmaceuticals (ALNY) Operating Cash Flow ComparisonFinancials 
8Alnylam Pharmaceuticals (ALNY) Net Income ComparisonFinancials 
9Alnylam Pharmaceuticals (ALNY) Operating Income ComparisonFinancials 
10Alnylam Pharmaceuticals (ALNY) Revenue ComparisonFinancials 
11ARTICLES  
12Now is not the time to buy Alnylam Pharmaceuticals stock August 21st, 2025
13Large Cap Stocks Trading At 52-Week High August 19th, 2025
14Large Cap Stocks Trading At 52-Week High August 7th, 2025
15ALNY Stock Up 29% after 5-Day Win Streak August 5th, 2025
16ALNY Stock in Focus: Does It Outshine the Peer Group? August 1st, 2025
Title
0DASHBOARDS
1Now is not the time to buy Alnylam Pharmaceuticals stock
2Large Cap Stocks Trading At 52-Week High
3Large Cap Stocks Trading At 52-Week High
4ALNY Stock Up 29% after 5-Day Win Streak
5ALNY Stock in Focus: Does It Outshine the Peer Group?
6ARTICLES
7Alnylam Pharmaceuticals Earnings Notes
8Now Is Not The Time To Buy Alnylam Pharmaceuticals Stock
9Day 5 of Gains Streak for Alnylam Pharmaceuticals Stock with 29% Return (vs. 78% YTD) [8/4/2025]
10ALNY Dip Buy Analysis
11Alnylam Pharmaceuticals Market Price
12Alnylam Pharmaceuticals Total Shareholder Return (TSR): 22.9% in 2024 and 11.5% 3-yr compounded annual returns (above peer average)
13Alnylam Pharmaceuticals (ALNY) Operating Cash Flow Comparison
14Alnylam Pharmaceuticals (ALNY) Net Income Comparison
15Alnylam Pharmaceuticals (ALNY) Operating Income Comparison
16Alnylam Pharmaceuticals (ALNY) Revenue Comparison

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO9734.4% 
3CHSNChanson International7565.0%-99.3%
4LNZALanzaTech Global7287.5%-86.0%
5QMMMQMMM3031.7%6775.0%
6OESXOrion Energy Systems1497.9%22.9%
7CURXCuranex Pharmaceuticals1401.6%1401.6%
8ENTOEntero Therapeutics565.6%117.6%
9PTNMPitanium553.2% 
10WLDSWearable Devices449.5%-30.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-92.2%-95.0%
2STFSStar Fashion Culture-92.2%-97.8%
3ELPWElong Power-91.6%-76.7%
4NXTTNext Technology-89.6%-95.1%
5NAKAKindly MD-89.0% 
6BINIBollinger Innovations-88.9%-100.0%
7JEM707 Cayman-88.4%-98.2%
8YAASYouxin Technology-82.5%-98.3%
9NEONNeonode-82.0%-50.2%
10NVNOenVVeno Medical-81.5%-69.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Alnylam Pharmaceuticals

Financials

ALNYIONSSRPTNTLAABBVAMGNMedian
NameAlnylam .Ionis Ph.Sarepta .Intellia.AbbVie Amgen  
Mkt Price461.2461.3118.1012.27216.26273.08138.79
Mkt Cap59.89.71.81.3382.3146.934.8
Rev LTM2,3487172,4825358,32834,9172,415
Op Inc LTM-115-472-1-51213,6958,192-58
FCF LTM-75-563-454-42218,23910,605-249
FCF 3Y Avg-184-438-505-39620,2738,590-290
CFO LTM-45-502-301-41919,28312,013-173
CFO 3Y Avg-131-401-395-38721,1549,753-259

Growth & Margins

ALNYIONSSRPTNTLAABBVAMGNMedian
NameAlnylam .Ionis Ph.Sarepta .Intellia.AbbVie Amgen  
Rev Chg LTM17.2%-7.6%64.9%15.0%6.1%12.9%13.9%
Rev Chg 3Y Avg40.8%-1.4%45.0%6.2%0.6%10.0%8.1%
Rev Chg Q20.2%10.1%68.4%104.8%6.6%9.4%15.2%
QoQ Delta Rev Chg LTM4.4%1.7%11.1%16.0%1.7%2.3%3.4%
Op Mgn LTM-4.9%-65.9%-0.0%-968.7%23.5%23.5%-2.5%
Op Mgn 3Y Avg-27.5%-65.7%-16.1%-991.9%27.2%26.4%-21.8%
QoQ Delta Op Mgn LTM3.0%1.5%5.2%218.7%1.0%1.6%2.3%
CFO/Rev LTM-1.9%-70.0%-12.1%-791.9%33.1%34.4%-7.0%
CFO/Rev 3Y Avg-13.1%-59.0%-29.1%-766.0%37.5%32.0%-21.1%
FCF/Rev LTM-3.2%-78.5%-18.3%-798.0%31.3%30.4%-10.8%
FCF/Rev 3Y Avg-16.6%-64.4%-35.5%-785.0%36.0%28.2%-26.1%

Valuation

ALNYIONSSRPTNTLAABBVAMGNMedian
NameAlnylam .Ionis Ph.Sarepta .Intellia.AbbVie Amgen  
Mkt Cap59.89.71.81.3382.3146.934.8
P/S25.513.60.724.16.64.210.1
P/EBIT-284.6-25.8-354.3-2.564.914.2-14.1
P/E-221.8-21.2-30.6-2.7101.622.2-11.9
P/CFO-1,325.9-19.4-5.9-3.019.812.2-4.5
Total Yield-0.5%-4.7%-3.3%-37.7%3.9%7.9%-1.9%
Dividend Yield0.0%0.0%0.0%0.0%3.0%3.4%0.0%
FCF Yield 3Y Avg-0.8%-7.0%-12.0%-23.9%7.3%6.2%-3.9%
D/E0.00.10.80.10.20.40.2
Net D/E-0.0-0.10.3-0.30.20.30.1

Returns

ALNYIONSSRPTNTLAABBVAMGNMedian
NameAlnylam .Ionis Ph.Sarepta .Intellia.AbbVie Amgen  
1M Rtn2.7%40.1%-17.0%11.6%4.6%-7.9%3.7%
3M Rtn49.4%69.6%-16.0%28.1%17.6%-5.1%22.8%
6M Rtn88.8%86.1%-75.4%33.5%2.9%-12.8%18.2%
12M Rtn70.6%50.7%-85.4%-43.0%14.4%-15.8%-0.7%
3Y Rtn116.5%32.3%-83.8%-81.3%68.0%30.0%31.2%
1M Excs Rtn0.3%37.6%-19.4%9.2%2.2%-10.3%1.3%
3M Excs Rtn39.9%64.5%-23.1%27.4%4.8%-16.4%16.1%
6M Excs Rtn65.8%62.3%-98.6%11.7%-13.8%-28.9%-1.1%
12M Excs Rtn58.2%31.4%-103.6%-58.7%-2.6%-32.6%-17.6%
3Y Excs Rtn44.2%-31.5%-147.2%-143.4%8.7%-41.1%-36.3%

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date5/1/20252/13/202510/31/20248/1/20245/2/20242/15/202411/2/20238/3/20235/4/20232/23/202310/27/20227/28/2022
Key Financials Quarterly            
Total Revenue594593501660494440751319319335264225
Ebitda11-155-4759-15-106205-221-117-177-344-212
Operating Income18-105-7749-43-116214-230-150-189-258-192
Net Income-57-84-112-17-66-138148-276-174-207-406-277
EPS-0.44-0.65-0.87-0.13-0.52-1.101.18-2.21-1.40-1.68-3.32-2.29
Key Financials TTM            
Total Revenue TTM2,3482,2482,0952,3442,0031,8281,7241,2371,1431,037961884
Ebitda TTM-132-158-110143-137-239-310-859-850-910-935-732
Operating Income TTM-115-177-188103-176-282-354-826-788-785-791-715
Net Income TTM-270-278-332-73-332-440-510-1,064-1,065-1,131-1,182-981
Growth Rates Quarterly            
Total Revenue Growth20.2%34.9%-33.3%107.0%54.8%31.2%184.0%41.8%49.7%29.6%40.9%1.9%
EBITDA Growth177.3%-45.7%-123.0%126.6%87.4%40.0%159.6%-4.2%33.8%12.3%-144.6%-72.9%
Operating Income Growth141.6%9.7%-136.0%121.2%71.0%38.3%182.9%-19.9%-2.1%3.1%-42.0%-31.1%
Net Income Growth12.8%39.2%-175.5%93.9%62.1%33.6%136.4%0.5%27.6%19.7%-98.5%-46.3%
Margins Quarterly            
EBITDA Margin1.9%-26.1%-9.4%8.9%-3.0%-24.2%27.3%-69.2%-36.7%-52.9%-130.2%-94.2%
Operating Income Margin3.0%-17.7%-15.4%7.4%-8.8%-26.5%28.5%-72.1%-46.9%-56.3%-97.6%-85.3%
Net Income Margin-9.7%-14.1%-22.3%-2.6%-13.3%-31.4%19.7%-86.6%-54.5%-61.9%-153.6%-123.4%
Cash & Debt            
Total Cash2,6322,6952,7802,6252,3712,4392,4062,0582,0712,1922,2652,111
Total Debt1,3021,2961,3021,3041,3011,3051,3091,3141,3201,3201,324991
Net Debt / (Cash)-1,331-1,398-1,478-1,321-1,070-1,134-1,097-743-750-872-941-1,120
Cash Flows Quarterly            
FCF from Operations-118-9544124-82-30359-59-166-132-115-123
Cash Flows TTM            
FCF from Operations TTM-45-8573721891042-473-537-541-559-578
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC1.2%-3.0%-5.3%3.4%-3.0%-8.2%15.0%-15.7%-10.5%-13.6%-19.3%-15.3%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-1.4%-2.2%-3.3%1.8%-3.0%-5.0%-6.3%-14.1%-13.7%-14.2%-14.8%-14.3%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
AMVUTTRA558940  
Net revenues from collaborations54613518113153
ONPATTRO355558475306166
GIVLAARI219173128550
OXLUMO11070600 
Royalty revenue4181  
Total1,8281,037844493220


Price Behavior

ALNY Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.02-0.27-0.130.931.010.91
Up Beta-0.57-0.20-0.130.740.800.90
Down Beta-0.64-1.10-0.831.301.201.20
Up Capture119%165%123%154%156%63%
Bmk +ve Days10223571142415
Stock +ve Days14273975128370
Down Capture-100%-254%-174%50%94%91%
Bmk -ve Days11192754106334
Stock -ve Days7142350120379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity3,973,434
Short Interest: % Change Since 815202516.0%
Average Daily Volume1,064,147
Days-to-Cover Short Interest3.73
Basic Shares Quantity129,676,000
Short % of Basic Shares3.1%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/31/202515.4%26.0%33.1%
2/15/2024-10.2%-0.8%-9.1%
11/2/20232.9%7.9%9.2%
8/3/20231.7%-0.3%5.8%
5/4/20233.0%5.7%-2.9%
1/9/2023-2.3%4.7%-1.8%
10/27/2022-3.5%6.6%5.8%
7/28/20221.1%49.3%50.7%
...
SUMMARY STATS   
# Positive10119
# Negative10911
Median Positive2.3%6.6%13.2%
Median Negative-3.7%-7.5%-6.6%
Max Positive15.4%49.3%50.7%
Max Negative-15.2%-9.6%-18.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025731202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024213202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024502202410-Q 3/31/2024
12312023215202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022223202310-K 12/31/2022
93020221027202210-Q 9/30/2022
6302022728202210-Q 6/30/2022
3312022428202210-Q 3/31/2022
12312021210202210-K 12/31/2021
93020211028202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Reitan Colleen F 5122025Buy286.00329,1529,152Form
1Garg PushkalCMO & EVP Dev & Med Affairs3252025Sell285.004,3211,231,4855,762,985Form
2Fitzgerald Kevin JosephCSO & EVP, Head of Research3032025Sell236.51276,3863,040,100Form
3Garg PushkalCMO & EVP Dev & Med Affairs12132024Sell247.4812129,9454,290,313Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.